Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- FUDR (floxuridine)
- rilonacept
Interactions between your drugs
floxuridine rilonacept
Applies to: FUDR (floxuridine), rilonacept
GENERALLY AVOID: The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution. Interleukin-1 blockers should be discontinued if neutropenia or serious infection occurs.
References (3)
- (2001) "Product Information. Kineret (anakinra)." Amgen
- (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc
- (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Alimta
Alimta is used to treat non-small cell lung cancer and mesothelioma, a form of lung cancer ...
Arranon
Arranon is used to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Clolar
Clolar is a cancer medicine that is used to treat acute lymphoblastic leukemia (a type of blood ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Folotyn
Folotyn is used to treat T-cell lymphoma that has spread throughout the body. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.